The value of adherence information during clinical pharmaceutical trials.

Emily N GrayekBaruch FischhoffAlexander L DavisTamar Krishnamurti

Published in: Clinical trials (London, England) (2022)

Our proposed approach can guide drug regulators and developers in designing efficient clinical trials and assessing the impact of nonadherence on trial results. It can identify cost-effective adherence-monitoring methods, given available knowledge about the methods, drug, and patients' expected adherence.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
healthcare
chronic kidney disease
phase ii
study protocol
peritoneal dialysis
transcription factor
randomized controlled trial
emergency department
adverse drug
skeletal muscle
metabolic syndrome
social media